Trial · NCT06875193
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Variance in HbA1c from baseline to 24 weeks on study drug | 24 weeks | Change in HbA1c |
| Secondary | Variance in HbA1c from baseline to 12 weeks on study drug | 12 weeks | Change in HbA1c |
| Secondary | Variance in FPG from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Change in Fasting Plasma Glucose(FPG) |
| Secondary | Variance in TC(mg/dL), TG(mg/dL), HDL(mg/dL), LDL(mg/dL) from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Change in TC, TG, HDL, LDL |
| Secondary | Variance in FLI(Fatty Liver Index), AST, ALT, r-GTP, ALP, HSI(Hepatic steatosis index), Total bilirubin, Albumin, Protein from baseline to 12 and 24 weeks after study drug administration | 12, 24 weeks | FLI(Fatty Liver Index)= 1/(1+exp(-x))×100 HSI(Hepatic steatosis index) = 8×ALT/AST+BMI(+2, if type 2 diabetes yes, +2 if female) |
| Secondary | Variance in Kidney value from baseline to 12, 24 weeks on study drug | 12, 24 weeks | Kidney value: eGFR(CKD-EPI fomulation) ACR(Albumin to Creatine ratio), Creatinine |
| Secondary | Variance in body weight from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Percentage of patients achieving HbA1c of 7.0% or 6.5% or less at 12 and 24 weeks post study drug administration compared to baseline | 12, 24 weeks | Percentage of patients achieving HbA1c of 7.0% or 6.5% or less |
| Secondary | Variance in Insulin from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Percentage of subjects prescribed an rescue drug during this study | during 24weeks(study duration/per subject) | rescue drug |
| Secondary | Variance in waist measurement from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Variance in BMI from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Variance in blood pressure from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Variance in HOMA-IR, HOMA-β(Glucose in Molar Units mmol/L) from baseline to 12, 24 weeks on study drug | 12, 24 weeks | |
| Secondary | Variance in c-peptide from baseline to 12, 24 weeks on study drug | 12, 24 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06875193/registered